\
&
Contact us
Health Culture and society Security Digital, Industry & Space
The open and forthcoming calls under Horizon Europe have been published on the Funding & Tenders Portal (Funding - Call for proposals) However, there are technical issues with the filter functions in Pillar 2: filtering per cluster does not display all 2025 call topics within this cluster and advertise call topics of other work programmes. The... read more
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.